This year’s American Diabetes Association’s (ADA) Scientific Sessions in Orlando, Florida highlighted some important JDRF-supported research underway, encompassing breakthrough clinical trials and significant research findings that are paving the way to novel and emerging treatments for T1D.
Two promising Australian research projects have been awarded almost $3 million in funding from The Leona M. and Harry B. Helmsley Charitable Trust, to be administered by JDRF Australia.
A T1DCRN funded clinical trial published in Diabetes Care has shown that a pump with the ability to suspend insulin delivery when blood glucose levels begin to fall can reduce hypoglycaemic episodes without deterioration in glycaemic control.
The integration of real-time continuous glucose monitoring systems and pump therapy has been an important milestone in the management of type 1 diabetes, and advances in the technology field offers the potential to further improve clinical outcomes.
Senator The Hon Simon Birmingham, Minister for Education and Training, and The Hon Greg Hunt MP, Minister for Health and Minister for Sport, have today announced the recipients of Innovation Award grants for research into type 1 diabetes.
Three bold, promising research projects have been selected and will benefit from $4.5 million in funding from the Type 1 Diabetes Clinical Research Network (T1DCRN), itself an innovative clinical research program led by JDRF Australia and funded by a Special Research Initiative through the Australian Research Council (ARC).
In an exciting paradigm shift that aims to accelerate patient impact, the research funded by the Innovation Award grants will explore new directions in the search for a cure for type 1 diabetes, including concepts that have never before been investigated.
A report by leading type 1 diabetes experts from around the world has for the first time provided consensus on managing blood glucose levels safely while exercising.
The report, ‘Exercise management in type 1 diabetes: a consensus statement’ was published in the Lancet Diabetes and Endocrinology journal and involved a team of 21 researchers, including T1DCRN researchers Professor Tim Jones, Professor Paul Fournier and Dr Carmel Smart. They undertook a review of current published studies to understand the activity levels of those living with type 1 diabetes and how different types of exercise affect blood glucose levels. Read More
JDRF is proud to congratulate Professor Mark Cooper, Head of Diabetes in the Faculty of Medicine, Nursing and Health Sciences at Monash University, who was awarded an AO (Officer in the General Division of the Order of Australia) on Australia Day this month.
This award is the most prestigious means of recognising outstanding members of the community at a national level.
Minister Simon Birmingham has announced that nearly $4 million has been awarded to Australian researchers for the Type 1 Diabetes Clinical Research Network (T1DCRN) Australasian Diabetes Data Network (ADDN) and Career Development Awards.
Giving probiotics to babies in the first few weeks of life may lower their risk of developing type 1 diabetes, a recent study has found.
The study, published in JAMA Pediatrics found that children who were given probiotics within the first 27 days of life had a 60% reduction in the risk of developing islet autoimmunity, compared with children who were first given probiotics after 27 days or not at all. Read More
JDRF partner Sanofi and Lexicon Pharmaceuticals have announced a new collaboration to develop and commercialise a new oral drug for the treatment of type 1 diabetes.
The drug is called sotagliflozin and is used in conjunction with insulin to help improve blood glucose levels by blocking glucose absorption in the kidneys and the gut. Read More
The Australian Type 1 Diabetes Clinical Research Network has partnered with the Immune Tolerance Network to launch a new Australian clinical trial to slow the development of newly diagnosed type 1 diabetes in children.
The EXTEND-P trial is expected to begin recruitment in March 2016 to test the ability of an existing drug called tocilizumab to preserve beta cell function. Tocilizumab, sold under the brand name Actemra, is currently approved for use in children with juvenile arthritis. Read More